Withholding Apixaban (Eliquis) Prior to ORIF Surgery
For ORIF surgery, which is a high bleeding risk procedure, apixaban should be stopped 3 days before surgery (skip 4 doses) in patients with normal or mildly impaired renal function (CrCl ≥50 mL/min), and 4 days before surgery (skip 6 doses) in patients with moderate renal impairment (CrCl 30-50 mL/min). 1
Preoperative Management Algorithm
Step 1: Assess Renal Function
The timing of apixaban discontinuation is critically dependent on kidney function because 25% of the drug is renally cleared 1:
- Normal or mild renal impairment (CrCl ≥50 mL/min): Stop apixaban 3 days before surgery (skip 4 doses)
- Moderate renal impairment (CrCl 30-50 mL/min): Stop apixaban 4 days before surgery (skip 6 doses)
Step 2: Understand the Rationale
ORIF is classified as a high bleeding risk surgery due to the extensive soft tissue dissection, bone work, and difficulty controlling bleeding in the surgical field. The goal is to achieve minimal residual anticoagulant effect (≤6%) at the time of surgery 1. With apixaban's half-life of 7-8 hours, stopping 3 days before surgery allows approximately 4-5 half-lives to elapse, which eliminates >90% of the drug's anticoagulant effect 1.
The FDA label for Eliquis confirms this approach, stating that apixaban should be discontinued at least 48 hours prior to elective surgery with moderate or high bleeding risk 2. However, the more conservative guideline recommendation of 3 days (72 hours) for high-risk procedures like ORIF provides an additional safety margin 1.
Step 3: Consider Bridging Therapy
Bridging anticoagulation is NOT recommended during the 24-72 hours after stopping apixaban and prior to ORIF 2. The short half-life of apixaban means the interruption period is brief enough that bridging is unnecessary and would only increase bleeding risk. This differs from warfarin management where bridging may be considered in high-risk patients 1.
Postoperative Resumption
After ORIF, apixaban should be resumed cautiously:
- Resume 2-3 days after surgery (48-72 hours postoperatively) once adequate hemostasis is established 1
- Consider starting with a reduced dose (2.5 mg twice daily) for the first 2-3 days in patients at high risk for thromboembolism, then increase to full dose (5 mg twice daily) 1
- The timing depends on achieving adequate wound hemostasis and assessing ongoing bleeding risk
Critical Caveats and Pitfalls
Avoid these common errors:
Don't use the 2-day interruption protocol for ORIF: Some guidelines suggest 2-day interruption for low bleeding risk procedures 3, but ORIF is definitively high-risk and requires the longer 3-day interruption 1
Don't forget to adjust for renal function: Patients with CrCl 30-50 mL/min need an extra day of interruption (4 days total) because apixaban clearance is prolonged 1
Don't resume too early postoperatively: The rapid onset of apixaban's anticoagulant effect (peak at 3-4 hours) means premature resumption significantly increases bleeding risk 1. Wait until 48-72 hours post-ORIF when hemostasis is secure.
Don't bridge with LMWH: Unlike warfarin protocols, apixaban's short half-life makes bridging unnecessary and potentially dangerous 2
Supporting Evidence Quality
The primary recommendations come from a 2012 Blood guideline 1 that provides the most comprehensive and widely-cited perioperative DOAC management protocol. This is reinforced by the 2022 CHEST guideline 4 and the PAUSE study, which demonstrated that standardized DOAC interruption (2 days before low-risk, 4 days total for high-risk procedures) resulted in low rates of both thromboembolism (0.16%) and major bleeding (1.35%) 4. The FDA label 2 provides regulatory support for at least 48-hour interruption for moderate-to-high bleeding risk procedures.
A 2022 observational study 5 confirmed that apixaban discontinuation for at least 48 hours resulted in clinically insignificant anticoagulation levels (94% of patients had levels ≤30 ng/mL), validating the safety of this approach in real-world practice.